Cure My Disease

Don't miss your cure!

 Log in / Sign up

A common amino acid may shield kidneys after heart surgery — a massive analysis puts it to the test

NCT ID NCT07718373

Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

Acute kidney injury is a frequent and serious complication after cardiac surgery, and effective prevention remains elusive. This study analyzes data from 5,000 adults who had heart surgery with a heart-lung machine to see whether giving the amino acid L-arginine within the first three days after surgery lowers their risk of kidney damage. L-arginine is a building block for nitric oxide, a molecule that helps blood vessels relax and may improve kidney blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
the amino acid L-arginine given intravenously within the first three days after heart surgery
What this could lead to
If L-arginine proves protective, it could offer a simple, low-cost way to reduce kidney damage after cardiac surgery.
What could go wrong
This is an observational analysis, not a randomized trial, so results may be influenced by other factors. L-arginine can also cause side effects like low blood pressure or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adults admitted to the ICU after CPB-assisted cardiac surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: ·adults admitted to the ICU after CPB-assisted cardiac surgery Exclusion Criteria: * congenital heart disease, * surgery requiring deep hypothermic circulatory arrest, * a preoperative baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², * AKI already present prior to ICU admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.